Inhibition of DYRK1A hyperactivity in AD by quercetin in the brain may pave the way for therapies on cognitive decline in AD patients (Smith et al., 2012; Branca et al., 2017; Pathak et al., 2018). This evidence concerns the gene DYRK1A and Alzheimer disease.